These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 25906289)

  • 1. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
    Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H
    J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group.
    Myšíková D; Adkins I; Hradilová N; Palata O; Šimonek J; Pozniak J; Kolařík J; Skallová-Fialová A; Špíšek R; Lischke R
    J Thorac Oncol; 2017 Feb; 12(2):249-257. PubMed ID: 27793776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
    Dong J; Zeng BH; Xu LH; Wang JY; Li MZ; Zeng MS; Liu WL
    J Transl Med; 2010 Sep; 8():81. PubMed ID: 20813067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis.
    Yang J; Jiao S; Kang J; Li R; Zhang G
    Int J Clin Exp Pathol; 2015; 8(11):14959-64. PubMed ID: 26823828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1.
    Türeci O; Mack U; Luxemburger U; Heinen H; Krummenauer F; Sester M; Sester U; Sybrecht GW; Sahin U
    Cancer Lett; 2006 May; 236(1):64-71. PubMed ID: 15992994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
    Kawada J; Wada H; Isobe M; Gnjatic S; Nishikawa H; Jungbluth AA; Okazaki N; Uenaka A; Nakamura Y; Fujiwara S; Mizuno N; Saika T; Ritter E; Yamasaki M; Miyata H; Ritter G; Murphy R; Venhaus R; Pan L; Old LJ; Doki Y; Nakayama E
    Int J Cancer; 2012 Feb; 130(3):584-92. PubMed ID: 21413013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers.
    Hoshino I; Nabeya Y; Takiguchi N; Gunji H; Ishige F; Iwatate Y; Shiratori F; Yajima S; Okada R; Shimada H
    Ann Gastroenterol Surg; 2020 May; 4(3):275-282. PubMed ID: 32490341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
    Stockert E; Jäger E; Chen YT; Scanlan MJ; Gout I; Karbach J; Arand M; Knuth A; Old LJ
    J Exp Med; 1998 Apr; 187(8):1349-54. PubMed ID: 9547346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NY-ESO-1 expression and immunogenicity in esophageal cancer.
    Fujita S; Wada H; Jungbluth AA; Sato S; Nakata T; Noguchi Y; Doki Y; Yasui M; Sugita Y; Yasuda T; Yano M; Ono T; Chen YT; Higashiyama M; Gnjatic S; Old LJ; Nakayama E; Monden M
    Clin Cancer Res; 2004 Oct; 10(19):6551-8. PubMed ID: 15475443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
    Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
    Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NY-ESO-1 antibody as a novel tumour marker of gastric cancer.
    Fujiwara S; Wada H; Kawada J; Kawabata R; Takahashi T; Fujita J; Hirao T; Shibata K; Makari Y; Iijima S; Nishikawa H; Jungbluth AA; Nakamura Y; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Nakayama E; Mori M; Doki Y
    Br J Cancer; 2013 Mar; 108(5):1119-25. PubMed ID: 23403818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
    Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
    Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma.
    Xu YW; Peng YH; Chen B; Wu ZY; Wu JY; Shen JH; Zheng CP; Wang SH; Guo HP; Li EM; Xu LY
    Am J Gastroenterol; 2014 Jan; 109(1):36-45. PubMed ID: 24296751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors.
    Sugita Y; Wada H; Fujita S; Nakata T; Sato S; Noguchi Y; Jungbluth AA; Yamaguchi M; Chen YT; Stockert E; Gnjatic S; Williamson B; Scanlan MJ; Ono T; Sakita I; Yasui M; Miyoshi Y; Tamaki Y; Matsuura N; Noguchi S; Old LJ; Nakayama E; Monden M
    Cancer Res; 2004 Mar; 64(6):2199-204. PubMed ID: 15026363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum.
    Kilic A; Schuchert MJ; Luketich JD; Landreneau RJ; Lokshin AE; Bigbee WL; El-Hefnawy T
    J Thorac Cardiovasc Surg; 2008 Jul; 136(1):199-204. PubMed ID: 18603076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.
    Ademuyiwa FO; Bshara W; Attwood K; Morrison C; Edge SB; Karpf AR; James SA; Ambrosone CB; O'Connor TL; Levine EG; Miliotto A; Ritter E; Ritter G; Gnjatic S; Odunsi K
    PLoS One; 2012; 7(6):e38783. PubMed ID: 22761704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
    Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
    PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum autoantibodies in the early detection of esophageal cancer: a systematic review.
    Zhang H; Xia J; Wang K; Zhang J
    Tumour Biol; 2015 Jan; 36(1):95-109. PubMed ID: 25433500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-panel assay of serum autoantibodies in colorectal cancer.
    Ushigome M; Nabeya Y; Soda H; Takiguchi N; Kuwajima A; Tagawa M; Matsushita K; Koike J; Funahashi K; Shimada H
    Int J Clin Oncol; 2018 Oct; 23(5):917-923. PubMed ID: 29691673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
    Akcakanat A; Kanda T; Koyama Y; Watanabe M; Kimura E; Yoshida Y; Komukai S; Nakagawa S; Odani S; Fujii H; Hatakeyama K
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):95-100. PubMed ID: 15118836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.